Renaissance Technologies (RenTech)'s RLMD Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 57,800 shares of Relmada Therapeutics, Inc. (RLMD) worth $399,976, representing 0.00% of the portfolio. First purchased in 2021-Q3, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in RLMD, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2022, adding 217,810 shares. Largest reduction occurred in Q2 2023, reducing 180,403 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Relmada Therapeutics (RLMD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Relmada Therapeutics (RLMD) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -109,400 | Reduce 65.43% | 57,800 | $6.92 |
| Q1 2026 | -17,800 | Reduce 9.62% | 167,200 | $6.96 |
| Q4 2025 | +15,300 | Add 9.02% | 185,000 | $4.83 |
| Q3 2025 | +19,600 | Add 13.06% | 169,700 | $2.01 |
| Q2 2025 | +26,000 | Add 20.95% | 150,100 | $0.60 |
| Q1 2025 | -40,413 | Reduce 24.57% | 124,100 | $0.27 |
| Q4 2024 | +138,625 | Add 535.48% | 164,513 | $0.52 |
| Q3 2024 | -62,887 | Reduce 70.84% | 25,888 | $3.24 |
| Q2 2024 | +53,767 | Add 153.58% | 88,775 | $3.00 |
| Q1 2024 | -111,881 | Reduce 76.17% | 35,008 | $4.66 |
| Q4 2023 | +81,614 | Add 125.03% | 146,889 | $4.14 |
| Q3 2023 | -67,497 | Reduce 50.84% | 65,275 | $3.00 |
| Q2 2023 | -180,403 | Reduce 57.60% | 132,772 | $0.00 |
| Q1 2023 | +95,365 | Add 43.78% | 313,175 | $0.00 |
| Q4 2022 | +217,810 | New Buy | 217,810 | $0.00 |
| Q1 2022 | -14,400 | Sold Out | 0 | $0.00 |
| Q4 2021 | -1,100 | Reduce 7.10% | 14,400 | $22.50 |
| Q3 2021 | +15,500 | New Buy | 15,500 | $26.19 |
Renaissance Technologies (RenTech)'s Relmada Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Relmada Therapeutics, Inc. (RLMD) in Q3 2021, acquiring 15,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Relmada Therapeutics, Inc. (RLMD) for 18 quarters since Q3 2021.
Renaissance Technologies (RenTech)'s largest addition to Relmada Therapeutics, Inc. (RLMD) was in Q4 2022, adding 217,810 shares worth $760.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 57,800 shares of Relmada Therapeutics, Inc. (RLMD), valued at approximately $399,976.
As of the Q2 2026 filing, Relmada Therapeutics, Inc. (RLMD) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Relmada Therapeutics, Inc. (RLMD) was 313,175 shares, as reported at the end of Q1 2023.